Taksta: Ph III data

Top-line data from 716 ABSSSI patients in the ITT population of a double-blind, U.S. Phase III trial showed that oral Taksta met the primary endpoint of non-inferiority to oral linezolid in early

Read the full 323 word article

How to gain access

Continue reading with a
two-week free trial.